Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:AEZS - Post Discussion

COSCIENS Biopharma Inc > Down 13% since merger announced
View:
Post by lscfa on Jun 09, 2024 2:38pm

Down 13% since merger announced

$11.60 ---> $10.08
Comment by Hopeforthebest on Jun 12, 2024 11:53am
It is now down to to $9.10 since your post 22% since the annoucement. gagnon HAS TO GO HE IS INCAPABLE OF PROVIDING ANY SHAREHOLDER VALUE. SINCE HE HAS TAKEN CONTROL OF AEZS AND CZO HE HAS NO PROVIDED ANY SHAREHOLDER VALUE ONLY DIRECTOR VALUE IN DRAINING THE COMPANIES HE HAS RUN, CZO, AEZS AND JUVENITE. AT THE RATE WE ARE GOING I FORESEE ANOTHER STOCK SPLIT WITHIN THE NEXT COUPLE MONTHS TO ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities